Iron Deficiency in Heart Failure Clinical Trials — A Patient's Guide

Why iron deficiency matters in heart failure

Iron is more than what makes your blood count look normal. It is essential for how your muscles — including the heart muscle — produce energy. In heart failure, the body struggles to keep up with normal energy demand, and being short on iron makes that worse.

Two facts that surprise most patients:

• Roughly 30-50% of stable heart failure patients are iron-deficient. It is one of the most common conditions that goes alongside heart failure.
• You can be iron-deficient without being anemic. Your hemoglobin (the standard "blood count" number) can look perfectly normal while the iron stores in your body are depleted. That is why doctors look at additional labs in heart failure patients: ferritin (a marker of stored iron) and transferrin saturation (TSAT) (a marker of how much iron is available for use).

When iron is low, heart failure symptoms tend to be worse: more fatigue, more shortness of breath, less exercise tolerance, and a lower quality of life. Studies have linked iron deficiency to higher rates of hospitalization in heart failure patients.

There is one more piece that matters for treatment. Oral iron pills often do not absorb well in heart failure patients because of the chronic inflammation that comes with the disease. That is the main reason intravenous (IV) iron has become a focus in heart failure care: it bypasses the absorption problem by going directly into the bloodstream.

If you do not know your ferritin or TSAT numbers off the top of your head, that is fine. They will be checked at screening. Bringing your most recent labs and a recent echocardiogram report (for your ejection fraction) helps.

What iron-deficiency-in-HF trials are testing in 2026

Research in this space has moved past the basic question of "does IV iron help heart failure patients with iron deficiency?" Most current trials are asking sharper, more specific questions:

• Different IV iron formulations. Several IV iron products exist (ferric derisomaltose, ferric carboxymaltose, iron sucrose, others). Trials compare them on safety, how quickly they raise iron stores, how convenient the dosing is (one large dose versus several smaller doses), and how often re-dosing is needed.
• Hard outcomes, not just labs. Older trials focused on whether IV iron raised ferritin and improved symptoms. Current trials are looking at hard endpoints: heart failure hospitalizations, cardiovascular death, all-cause mortality, and quality-of-life scores measured with validated tools like the Kansas City Cardiomyopathy Questionnaire.
• HFpEF-specific trials. Most of the historical IV iron data came from HFrEF (Heart Failure with reduced Ejection Fraction). Newer studies are extending into HFpEF (Heart Failure with preserved Ejection Fraction) to find out whether iron repletion helps that population too.
• Repeat dosing strategies. Iron deficiency tends to come back over time in heart failure. Trials are studying whether scheduled repeat dosing (for example, every 6 or 12 months) leads to better outcomes than waiting for symptoms to return.
• Alternative iron-related approaches. A smaller group of trials is exploring oral therapies designed for the inflammatory state of heart failure, hepcidin-pathway modulation, and other ways of correcting iron deficiency without IV.

A trial is not a guess. By the time a treatment reaches a Phase 3 iron-deficiency-in-HF study, it has already gone through earlier safety testing. The trial is asking a more specific question: does this work in real heart failure patients with iron deficiency, and how does it compare to current standard care?

Who might be eligible

Every iron-deficiency-in-HF trial has its own eligibility list. A few common requirements come up again and again:

• Confirmed heart failure — usually documented with an echocardiogram, plus a clinical diagnosis from a cardiologist. Both HFrEF and HFpEF populations are studied, depending on the trial.
• Iron deficiency by lab criteria. The most common thresholds — and the ones used by current ESC and AHA heart failure guidance — are ferritin less than 100 ng/mL, OR ferritin 100-299 ng/mL with TSAT less than 20%.
• Stable on guideline-directed medical therapy — already on the standard heart failure medicines your cardiologist recommends, at stable doses for a defined period (often 4 weeks or more).
• NYHA Class II-III symptoms — meaning you have noticeable symptoms with everyday activity (Class II) or marked limitation with less-than-ordinary activity (Class III). Many trials exclude Class I (no symptoms) and Class IV (symptoms at rest).
• Adequate kidney function, usually measured by eGFR above a trial-specific cutoff.
• No recent hospitalization for heart failure, often with a defined wait period after a heart failure admission.
• Ability to commit to IV infusion visits at the research site.
• Not pregnant or planning pregnancy during the study, for relevant patients.

You may also be excluded for things like active infection, active bleeding (which can cause iron loss for a different reason), recent IV iron administration outside the study, severe allergy to iron formulations, or being enrolled in another investigational study. None of these are personal — they are study-design decisions made to keep results clear and participants safe.

The honest reality: most patients who screen for any one trial do not end up enrolling in that specific trial. If you are not eligible for one, you may be eligible for another.

What participation involves

The general structure looks like this:

Screening (1-3 hours)

You meet the trial team. The Principal Investigator — a practicing cardiologist — reviews your history with you. You go through informed consent: a detailed document explaining what the trial is studying, what is involved, the known risks, and your right to leave at any time. (For a section-by-section walkthrough, see our consent-form reading guide.) Screening usually includes:

• An iron panel: ferritin, TSAT, serum iron, transferrin
• Hemoglobin and a basic blood count
• NT-proBNP and other heart failure labs
• An ECG
• Sometimes a recent or repeat echocardiogram review
• Six-minute walk test or quality-of-life questionnaire in some protocols

IV iron infusion visits (15-60 minutes at the site under monitoring)

If you are randomized to the IV iron arm, the infusion is given at the research site. Depending on the formulation, the infusion takes anywhere from about 15 minutes to about an hour. You are monitored before, during, and for a period after the infusion to watch for any reaction. Vital signs are checked routinely.

If you are randomized to a control arm (placebo or current standard care), you still come in on the same schedule and have the same monitoring, so neither you nor the team knows during the study which group you are in (in blinded trials).

Follow-up visits at 1, 3, and 6 months

Visits typically include:

• Repeat iron labs (ferritin, TSAT)
• Heart failure labs (NT-proBNP)
• Symptom and quality-of-life questionnaires
• Six-minute walk test in some protocols
• Review of any side effects
• Decision about whether a repeat infusion is needed (depends on protocol)

Many trials run for 12 months or longer with additional visits at later time points. A symptom or activity diary may be requested between visits.

End-of-study and follow-up

At the end of the trial-defined treatment phase, you have a final visit with closing assessments. Many trials add a follow-up period to monitor longer-term outcomes. After that, you return to your regular cardiologist for ongoing care.

What you might gain

Patients have different reasons for considering an iron-deficiency-in-HF trial. Common ones:

• Access to treatment for an under-treated problem. Iron deficiency in heart failure is often missed in routine care because patients are not anemic and ferritin is not always checked.
• More frequent heart failure monitoring — additional iron panels, NT-proBNP, ECGs, and check-ins with a cardiology team than routine care typically provides.
• Possible symptom improvement — fatigue, exercise tolerance, and quality of life have improved for some patients in prior IV iron studies. Improvement is not guaranteed for any individual patient.
• A meaningful contribution to research that may help future heart failure patients.

We want to be honest here: a trial may help you, may not change your symptoms, or in some cases may cause side effects. No one — not your cardiologist, not the trial team, not the sponsor — can promise benefit. That is exactly why the trial is being done: to find out.

What the risks are

IV iron trials are highly regulated, but participation does carry real risks. Patients should know about:

• Infusion reactions. The most common are mild and short-lived: flushing, headache, joint or muscle discomfort, brief changes in blood pressure, or nausea. These usually settle quickly. Serious allergic-type reactions are rare with modern IV iron formulations but can occur, which is why infusions are given under monitoring at the site.
• Randomization to a control arm. In many trials, you are randomly assigned to receive either the investigational treatment or a placebo / standard care. You may not get the investigational treatment.
• Heart failure worsening. Heart failure can worsen over time on its own, and that risk is monitored closely throughout the trial. The team adjusts your management as needed and an independent Data Safety Monitoring Board reviews trial data periodically.
• Time commitment. Infusion visits, labs, and monitoring take time and energy.
• Inconvenience and travel. Trial visits are at the research site, not at your regular cardiology clinic.

You can withdraw at any time, for any reason, without it affecting your future medical care.

How to find out if you are eligible

There are two easy ways to start the conversation:

• Call (786) 703-5941. A 15-minute eligibility screening is free and does not commit you to anything.
• Use our patient contact form at /contact-patient.

Bring or be ready to share the two key pieces of information that help us pre-screen quickly: a recent ferritin level (and TSAT if you have it) and your most recent ejection fraction from an echocardiogram. Also helpful: a list of your current heart failure medications and any recent heart failure hospitalizations.

Active iron-deficiency-in-HF trials at Amavita Research

We currently have iron-deficiency-in-HF protocols open at Amavita Research. As of the date on this page, an active study is:

• P-Monofer-CHF-02 (IV ferric derisomaltose) — a Phase 3 evaluation of intravenous ferric derisomaltose (Monofer) in patients with chronic heart failure and iron deficiency, sponsored by Pharmacosmos. See /trials/iv-ferric-derisomaltose for details.

For the current list of trials and contact information, see /therapeutic-areas/iron-deficiency-in-heart-failure. Trial availability changes — call us for the most current status.

If you would like a broader overview of heart failure trials beyond iron deficiency, see our companion guide: Heart Failure Clinical Trials — A Patient's Guide.

Questions worth asking before you join

The trial team welcomes these questions. If yours is not on the list, ask anyway.

• What ferritin and TSAT thresholds does this trial use? Different studies use slightly different cutoffs. The team can tell you whether your current numbers fit.
• How many infusions will I receive, and over what timeframe? Some trials use a single dose, some use a planned series, and some re-dose based on follow-up labs.
• What is the chance I will receive the investigational treatment versus placebo? This is set by the trial design and the team can tell you.
• Can I keep getting this treatment after the trial ends if it works for me? Sometimes, depending on the program. Ask about post-trial access if it matters to you.
• How will my regular cardiologist be kept in the loop? With your permission, we send updates and study data to your regular team so your care stays coordinated.
• What happens if my heart failure worsens during the study? The trial team manages it, may pause your participation if needed, and your regular medical care continues.
• Are there any costs to me? For most cardiovascular trials at Amavita Research, study-related care is paid for by the sponsor. Routine medical care is still billed to your insurance as usual.

---

About the author: Amavita Research is a cardiovascular clinical trial site embedded inside amavita Heart and Vascular Health® in North Miami Beach, FL. We have an on-site IV infusion suite for protocol-defined IV iron dosing, with same-day venous draws for ferritin, TSAT, NT-proBNP, and hemoglobin. Our PIs are practicing cardiologists. We see patients in English, Spanish, Haitian Creole, and Brazilian Portuguese. Call (786) 703-5941 or visit /contact-patient.